Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.JSC Pharmstandard has acquired 55% stake in a Ukrainian pharmaceutical company PJSC Biolek, which produces immunobiological, vaccines, serums, diagnostics products, culture mediums, blood products, hormonal, antiviral, antibacterial and enzymatic products.
Subscribe to our email newsletter
Pharmstandard is a Russian pharmaceutical company focused in R&D and production of the medicinal products.
Pharmstandard operates three modern pharmaceutical manufacturing facilities: JSC Pharmstandard-Leksredstva in Kursk, JSC Pharmstandard-UfaVITA in Ufa, JSC Pharmstandard-Tomskhimpharm in Tomsk and medical equipment factory JSC TZMOI in Tyumen.
Pharmstandard CEO Igor Krylov said for their company the purchase of Biolek is the first acquisition in the Ukraine.
"Pharmstandard’s current product range will be diversified with vaccines and serums, oncological and immunobiological drugs," Krylov said.
"Biolek’s products are largely sold in Russia and we are planning to increase sales within the Russian as well as overseas markets."